On 15 June 2022, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion1, recommending the granting of a marketing authorisation for the veterinary medicinal product DogStem, suspension for injection, intended for dogs. The applicant for this veterinary medicinal product is EquiCord S.L.
DogStem is a biological veterinary medicinal product containing equine umbilical cord-derived mesenchymal stem cells as the active substance. The product aims to reduce pain and lameness associated with osteoarthritis in dogs, through immunomodulatory and anti-inflammatory properties attributed to their paracrine activity.
The benefits of DogStem are its effects on reduction of pain and lameness associated with osteoarthritis in dogs.
The most common side effects are injection site reactions such as lameness and pain during the first week after administration and other mild site reactions such as limb swelling and heat during the first day after administration.
Detailed conditions for the use of this product will be described in the summary of product characteristics (SPC) which will be published in the European public assessment report (EPAR) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for DogStem and therefore recommends the granting of the marketing authorisation.
1 Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.
|Agency product number||
|International non-proprietary name (INN) or common name||
|Date opinion adopted||